US 12,435,132 B2
Anti-IL31 antibodies for veterinary use
Shyr Jiann Li, Millbrae, CA (US); Lam Nguyen, Union City, CA (US); and Hangjun Zhan, Foster City, CA (US)
Assigned to Elanco US Inc., Greenfield, IN (US)
Filed by Elanco US Inc., Greenfield, IN (US)
Filed on May 24, 2023, as Appl. No. 18/322,737.
Application 17/039,495 is a division of application No. 16/186,013, filed on Nov. 9, 2018, abandoned.
Application 16/186,013 is a division of application No. 15/844,142, filed on Dec. 15, 2017, granted, now 10,150,810, issued on Dec. 11, 2018.
Application 15/844,142 is a division of application No. 15/467,464, filed on Mar. 23, 2017, granted, now 10,093,731, issued on Oct. 9, 2018.
Application 18/322,737 is a continuation of application No. 17/039,495, filed on Sep. 30, 2020, granted, now 11,697,683.
Claims priority of provisional application 62/463,543, filed on Feb. 24, 2017.
Prior Publication US 2023/0365672 A1, Nov. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 2039/552 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 17 Claims
 
1. A method of reducing IL31 signaling in a canine cell or a feline cell, the method comprising exposing to the canine cell or the feline cell an antibody comprising:
a) (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1,
(ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2,
(iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3, and
b) (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 8,
(ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 9,
(iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 10.